Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 19

1.

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.

Wang H, Wang L, Lu Y, Chen X, Geng Q, Wang W, Xia Z.

Onco Targets Ther. 2016 Jan 28;9:587-95. doi: 10.2147/OTT.S97457. eCollection 2016.

2.

New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Paiva B, van Dongen JJ, Orfao A.

Blood. 2015 May 14;125(20):3059-68. doi: 10.1182/blood-2014-11-568907. Epub 2015 Apr 2. Review.

3.

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma.

Al-Mansour Z, Ramanathan M.

Adv Hematol. 2014;2014:652395. doi: 10.1155/2014/652395. Epub 2014 Nov 24. Review.

4.

Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.

Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN.

Biol Blood Marrow Transplant. 2015 Feb;21(2):335-41. doi: 10.1016/j.bbmt.2014.10.023. Epub 2014 Nov 1.

5.

The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.

He J, Yang L, Han X, Zheng G, Zheng W, Wei G, Wu W, Ye X, Shi J, Xie W, Li L, Zhang J, Huang W, Zhao Y, Huang H, Zhang X, Fu J, Cai Z.

PLoS One. 2014 Jun 11;9(6):e99174. doi: 10.1371/journal.pone.0099174. eCollection 2014.

6.

The future of autologous stem cell transplantation in myeloma.

van Rhee F, Giralt S, Barlogie B.

Blood. 2014 Jul 17;124(3):328-33. doi: 10.1182/blood-2014-03-561985. Epub 2014 Jun 3. Review.

7.

Current approaches to the initial treatment of symptomatic multiple myeloma.

Jasielec JK, Jakubowiak AJ.

Int J Hematol Oncol. 2013 Feb;2(1). doi: 10.2217/ijh.13.3.

8.

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.

Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA.

J Clin Oncol. 2013 Dec 20;31(36):4529-35. doi: 10.1200/JCO.2013.49.0086. Epub 2013 Nov 18.

9.

Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145.

Papanikolaou X, Heuck CJ, Barlogie B.

Haematologica. 2013 Nov;98(11):e149-50. doi: 10.3324/haematol.2013.098939. No abstract available.

10.

Association of response endpoints with survival outcomes in multiple myeloma.

Lonial S, Anderson KC.

Leukemia. 2014 Feb;28(2):258-68. doi: 10.1038/leu.2013.220. Epub 2013 Jul 19. Review.

11.

A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T.

Biol Blood Marrow Transplant. 2013 May;19(5):831-7. doi: 10.1016/j.bbmt.2013.02.013. Epub 2013 Feb 20.

12.

Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma.

Tosi P, Imola M, Mianulli AM, Tomassetti S, Merli A, Molinari A, Mangianti S, Ratta M, Isidori A, Visani G.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012069. doi: 10.4084/MJHID.2012.069. Epub 2012 Nov 5.

13.

Curability of multiple myeloma.

Alexanian R, Delasalle K, Wang M, Thomas S, Weber D.

Bone Marrow Res. 2012;2012:916479. doi: 10.1155/2012/916479. Epub 2012 May 23.

14.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S; International Myeloma Working Group.

Blood. 2011 Jun 9;117(23):6063-73. doi: 10.1182/blood-2011-02-297325. Epub 2011 Mar 29.

15.

Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent.

Jia D, Koonce NA, Halakatti R, Li X, Yaccoby S, Swain FL, Suva LJ, Hennings L, Berridge MS, Apana SM, Mayo K, Corry PM, Griffin RJ.

Radiat Res. 2010 Jun;173(6):809-17. doi: 10.1667/RR1734.1.

16.

Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.

Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S.

Mayo Clin Proc. 2010 Jun;85(6):532-7. doi: 10.4065/mcp.2009.0677.

17.

Current multiple myeloma treatment strategies with novel agents: a European perspective.

Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S.

Oncologist. 2010;15(1):6-25. doi: 10.1634/theoncologist.2009-0203. Epub 2010 Jan 19. Review.

18.

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Hoering A, Crowley J, Shaughnessy JD Jr, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B.

Blood. 2009 Aug 13;114(7):1299-305. doi: 10.1182/blood-2009-03-211953. Epub 2009 Jun 10.

19.

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J.

Blood. 2008 Oct 15;112(8):3115-21. doi: 10.1182/blood-2008-03-145235. Epub 2008 May 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk